Dystrophic Epidermolysis Bullosa

Dermatology·MeSH: Epidermolysis Bullosa Dystrophica

Prevalence

0.5 / 100K

15 drugs in development·11 companies·3 clinical trials

Drug Pipeline by Phase

Approved(3)

Drug	Company
d-fi	Ligand Pharmaceuticals Incorporated (LGND)
vyjuvek	Krystal Biotech, Inc. (KRYS)
zevaskyn	ABEONA THERAPEUTICS INC. (ABEO)

Phase 3(7)

Drug	Company
cordstrom	Inmune Bio, Inc. (INMB)
d-fi	Castle Biosciences Inc. (CSTL)
d-fi	XOMA Royalty Corporation (XOMA)
D-Fi	Crinetics Pharmaceuticals, Inc. (CRNX)
fcx-007	Castle Biosciences Inc. (CSTL)
kb803	Krystal Biotech, Inc. (KRYS)
rigosertib	TRAWS PHARMA, INC. (ONTX)

BLA Filed(2)

Drug	Company
prademagene zamikeracel (pz-cel)	ABEONA THERAPEUTICS INC. (ABEO)
pz-cel	ABEONA THERAPEUTICS INC. (ABEO)

Phase 1/Phase 2(2)

Drug	Company
agle-102	AGILE THERAPEUTICS INC (AGRX)
fcx-007	Fibrocell Science, Inc. (FCSC)

Phase 2/Phase 3(1)

Drug	Company
qrx004	Quoin Pharmaceuticals, Ltd. (QNRX)

BioSniper tracks 15 drugs in development for Dystrophic Epidermolysis Bullosa across 11 companies.

There are 3 clinical trials targeting Dystrophic Epidermolysis Bullosa tracked by BioSniper.

The estimated prevalence of Dystrophic Epidermolysis Bullosa is approximately 0.5 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.